Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.
HINOVA PHARMACEUTICALS INC. 
